Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report January – March 2018

Increased market presence results in greater interest for ChromoGenics’ dynamic glassesQ1 2018 · Net sales for the period amounted to SEK 1.9 (1.0) million. · Earnings for the period amounted to SEK -21.3 (-13.3) million, which corresponds to earnings per share of SEK -0.64 (-1.21). During the quarter, a provision was made for SEK 3.2 million related to the change in CEO. · Cash and cash equivalents as at March 31 amounted to SEK 48.3 million. · ChromoGenics invoiced final deliveries of dynamic glass to Atrium Ljungberg’s project Gränbystaden in Uppsala. · ChromoGenics

Moberg Pharma completes divestment of Balmex® for $4.25 million

STOCKHOLM, April 27th 2018, Moberg Pharma AB (OMX: MOB) has completed the divestment of the Balmex® brand to Randob Labs for a total consideration of $4.25 million plus the inventory value. The divestment results in a capital gain of circa $0.5 million.The brand Balmex®, with a number of products for treating and preventing diaper rash, was acquired from Chattem Inc. in April, 2015. The role of Balmex® in the product portfolio has reduced after the 2016 acquisitions. Divesting the brand, enables Moberg Pharma to focus resources on its larger and more profitable brands. The brand generated

Invitation to NetEnt’s Capital Markets Day on May 22

NetEnt invites analysts, investors and media to its capital markets day on May 22, 2018, at Convendum on Vasagatan 16 in Stockholm, Sweden. The event will start at 9:00 a.m. and end approximately at 14:30 p.m. CET.The first part of the day will include presentations by acting CEO Therese Hillman and Chief Product Officer Henrik Fagerlund, among others. The presentations will be focused on NetEnt’s overall strategy, products, markets and growth opportunities. The presentations will be held in English. After lunch, participants will also be given the opportunity to try out NetEnt´s

Preferential rights issue in NeuroVive oversubscribed

THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS.  Lund, April 27, 2018 - NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company") (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the outcome of the preferential rights issue of units consisting of shares and warrants, approved at the Extraordinary General Meeting on March 22, 2018 ("Rights Issue")

Stora Enso Interim Report January–March 2018

Accelerated profitable growth continues; promising start of the yearSTORA ENSO OYJ, Helsinki, FinlandINTERIM REPORT 27 April 2018 at 9.30 EESTQ1/2018 (year-on-year) · Sales increased by 3.3% to EUR 2 579 (2 497) million, primarily due to favourable prices and the ramp-up of strategic investments. · Operational EBIT increased 72% to EUR 369 (215) million as announced on 13 April, mainly due to favourable prices and mix optimisation combined with continued successful ramp-ups of the strategic investments. · The operational EBIT margin was 14.3% (8.6%), the highest for any

YIT and the City of Helsinki are planning a city block in Kruunuvuorenranta

YIT CORPORATION Press release, April 27, 2018, 09:30 a.m.YIT and the City of Helsinki are planning a city block in Kruunuvuorenranta The City of Helsinki has begun negotiations on the construction of a block in Kruunuvuorenranta with YIT Construction Ltd. YIT was selected as the negotiating partner in a competition organised by the city last autumn. The city was looking for a suitable concept and a contractor, and YIT and its consortium* presented the best preliminary plan. The city and YIT are collaborating on the development a project plan that will serve as the basis of a local

INTERIM REPORT 1 JANUARY – 31 MARCH 2018

First quarter 2018, compared to 2017, Group » Group net sales increased by 135% to SEK 1.1m (0.5) » Gross order intake amounted to SEK 0.9m (0.7) an increase of 10.1% » Order backlog amounted to SEK 0.5m (0.5) » 34% growth in orders for Episealer® knee implants during the quarter with 39 (29) approved orders » Loss before tax amounted to SEK –13.3m (–19.0) » Earnings per share (weighted average) amounted to SEK –0.44 (–0.94) Significant events during the first quarter » Episurf Medical continued regulatory preparations and industrial partnership discussions in the US

Resolutions at the Annual General Meeting in Biotage AB on April 26, 2018

At the Annual General Meeting held in Biotage AB (Reg. No. 556539-3138) on April 26, 2018, the following resolutions were passed, among others. Appropriation of the company’s resultThe General Meeting resolved a dividend of SEK 1.40 per share, which in aggregate is a dividend in the amount of no higher than SEK 90,600,226 and to carry forward SEK 380,532,356. Record date for dividend was resolved to be Monday 30 April 2018. Discharge, Board of Directors. Auditors etc.The General Meeting resolved to grant discharge to the Board of Directors and the Chief Executive Officer.

MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2018

Successful financing enables project portfolio advancementSignificant events during the quarter · The holders of series A shares have notified the Company that they will convert all their series A shares to series B shares. · Successful completion of pre-clinical safety studies with MIV-818, enabling start of phase I clinical studies in 2018. · Preclinical data on MIV-818 were presented at the 2018 HCC Summit organized by the European Association for the Study of the Liver. The data demonstrating targeting of the active metabolite to the liver and identifying potential biomarkers

Stillfront Group AB: Notice of AGM in Stillfront Group AB (publ)

Press ReleaseApril 27, 2018 Notice of annual general meeting in Stillfront Group AB (publ) The shareholders of Stillfront Group AB (publ), reg. no. 556721-3078 ("Company"), are hereby convened to the annual general meeting on Wednesday 30 May 2018 at 11.00 am. The general meeting will be held at the offices of the law firm Advokatfirma DLA Piper Sweden KB at Kungsgatan 9 in Stockholm. The right to participate at the general meeting etc.Shareholders who wish to participate at the general meeting shall i) be registered in the share register kept by Euroclear Sweden AB on the

Raisio plc’s interim report January-March 2018 will be published on 4 May 2018

Raisio plcPress release Raisio plc’s interim report January-March 2018 will be published on 4 May 2018 Raisio plc will publish its interim report January-March 2018 on Friday, 4 May 2018 at about 8:30 a.m. Finnish time. We will also publish President and CEO Pekka Kuusniemi’s video where he sums up the first quarter results. The video will be published at www.raisio.com. RAISIO PLC Heidi HirvonenCommunications and IR Managerheidi.hirvonen@raisio.comtel. +358 50 567 3060 Raisio plc Raisio is an international company specialised in healthy, responsibly produced

Stora Enso’s financial reports and AGM in 2019

STORA ENSO OYJ STOCK EXCHANGE RELEASE 27 April 2018 at 9.29 EESTFinancial report dates in 2019Stora Enso Oyj will publish four interim reports in 2019. The publication dates for financial information will be as follows: Friday   1 February 2019 Financial   Statement Release for 2018Thursday   25 April 2019 Interim Report for January–March 2019Friday   19 July 2019 Half-year Report for January–June 2019Tuesday   29 October 2019 Interim Report for January–September 2019 The financial reports are published at approximately 9.30 Finnish time. Stora Enso follows a silent

NextCell enters into Memorandum of Agreement with China General Consulting & Investment Co., Ltd.

NextCell Pharma AB ("NextCell") hereby announces that the company has entered a Memorandum of Agreement with China General Consulting & Investment Co., Ltd. (”CGCI”). The purpose of the agreement is to create a base for future co-operation. The agreement includes that the parties should prioritize working together when it comes to stem cell development and China, but is otherwise without claims or obligations and does not affect NextCell financially.NextCell has developed a patented applied for selection algorithm to ensure the selection and production of potent mesenchymal stem cells in

#18-727 Recalculation of reference value for certain instruments with Facebook Inc. as underlying security

The reference value for certain certificates with Facebook Inc. as underlying has been recalculated in accordance with the instruments final terms. This applies to the following instruments: Symbol: BEAR FB X10 C Symbol: BEAR FACEBK X8 VON The instrument will be traded under observation for the duration of this trading day. For more information concerning the recalculation, please contact the issuer of the affected instruments. For further information concerning this NGM notice please contact:NGM market surveillance, +46 8 566 390 55, marketsurveillance@ngm.se   Nordic

Leading service design agencies complete merger – goes to market as itch

IT- and management consultancy firm Acando has the last six months acquired two of Sweden’s leading service design agencies: Transformator Design and Daytona. As of today, the two agencies, together with two of Acando’s units within strategy and development, goes to market under the brand itch. itch is previously established as an Acando owned innovation agency, and will with the added capacity and competence now become the largest business design studio in Sweden.– Our business is built upon creating amazing and unforgettable customer experiences. And we’ve been brilliant at creating those

Heliospectra AB (publ) Interim Management Statement January – March 2018

Heliospectra Continues Growth with a 140 Percent Improvement in Recognized Revenue for Q1 Compared to Same Period Last Year (GOTHENBURG, Sweden/SAN FRANCISCO, CA, April 27th, 2018) – Heliospectra AB (publ) (OTCQB: HLSPY, FIRSTNORTH: HELIO), a world leader in intelligent lighting technology for controlled environments horticulture, today present their Interim Management Statement for January - March 2018.Turnover and profit/loss January - March · Net sales amounted to 9 374 (3 913) KSEK · Operating profit/loss amounted to -6 785 (-10 417) KSEK · Profit/loss after tax was -6 799

Report from the Annual General Meeting of Beijer Electronics Group AB (publ)

Beijer Electronics Group’s Annual General Meeting for the financial year 2017 was held on Thursday April 26, 2018. The AGM adopted all resolutions as earlier proposed by the Board of Directors and the Nomination Committee. A summary of the most important resolutions and a summary of the Annual General Meeting follows.The AGM approved the presented Income Statement and Balance Sheet and the Consolidated Income Statement and Consolidated Balance Sheet. The Board members and Chief Executive Officer were discharged from liability. The AGM decided not to distribute any dividend and that the

Report from the Annual General Meeting 2018 of AQ Group AB (publ)

AQ Group AB (publ) held its Annual General Meeting on April 26, 2018 at Culturen, 4:e teatern, Sintervägen 4, Västerås. The AGM adopted all resolutions as proposed by the Board of Directors.The most important resolutions were: DividendThe board's proposal of a dividend of SEK 2.75 SEK per share was adopted. Reconciliation date for the dividend will be Monday, April 30, 2018. Dividends will be paid out by Euroclear Sweden AB's on Friday, May 4, 2018. Number of board membersThe AGM decided that the board, until the next AGM, shall consist of seven elected members and no alternates.

Interim Report 1 January – 30 March 2018

“Growth continues”1 JANUARY – 31 MARCH 2018 (3 MONTHS) · Net sales rose by 4 percent to SEK 597 million (576). · EBITA rose by 7 percent to SEK 57 million (54), corresponding to an EBITA-margin of 9.6 percent (9.3). · Profit after tax amounted to SEK 26 million (29). · Cash flow from operating activities amounted to SEK 39 million (47). · Earnings per share amounted to SEK 1.09 (1.18). For the 12-month period, earnings per share amounted to SEK 4.86 (5.05). · The equity ratio amounted to 42 percent (40). · Return on working capital (P/WC) amounted to 64 percent (65).

Electrolux Q1 2018 interim report: Growth and solid earnings

Highlights of the first quarter of 2018·  Net sales amounted to SEK 27,906m (28,201). Sales growth was 3.3%, while currency translation had a negative impact of 4.4%. Strong organic sales growth in Major Appliances EMEA and Asia/Pacific. ·  Operating income amounted to SEK 764m (1,442), corresponding to a margin of 2.7% (5.1). ·  Operating income includes restructuring costs of SEK 596m relating to the consolidation of freezer production in North America. Excluding these costs, operating income amounted to SEK 1,360m, corresponding to a margin of 4.9%. ·  Product mix improvements

Immunovia Interim report, January-March 2018

“In the first quarter we reached a very important milestone for the company. Almost two years after the listing of Immunovia on Nasdaq First North, we received approval from Nasdaq to begin trading on their main market. We have also worked intensively towards our next milestone, which is to start sales by the end of 2018. The company has a target of achieving turnover of SEK 250-300 million by 2021 … and total turnover of SEK 800-1,000 by 2023.” Extract from comments to the interim report by CEO Mats Grahn.Key Indicators +--------------------+-----------+----------+--------------

Interim report January – March 2018

Cautious market for new production in Stockholm – stabilization of house prices in Sweden and NorwayRevenue decreased to SEK 4,054m (4,245) and operating profit decreased to SEK 528m (570). The operating margin amounted to 13.0 percent (13.4) Profit before tax decreased to SEK 512m (829) 1). Profit after tax decreased to SEK 399m (706) 1)  Return on equity for the past twelve months was 30.5 percent (36.1) 1). Earnings per share for the first quarter decreased to SEK 5.70 (9.90) 1)  Consolidated cash flow including net investment in properties was SEK –18m (1,001) The number of

Indutrade’s Annual General Meeting 2018

Indutrade’s Annual General Meeting adopted on Thursday the Board of Directors’ motion that a dividend of SEK 3.75 per share be paid for the 2017 fiscal year. The record date for dividend was set to 30 April 2018 and payment is expected to be distributed on 4 May 2018. Susanna Campbell, Bengt Kjell, Ulf Lundahl, Katarina Martinson, Krister Mellvé, Lars Pettersson and Bo Annvik were re-elected as directors. Anders Jernhall was elected as new board member. Katarina Martinson was elected as new chairman of the board. The previous chairman of the board, Fredrik Lundberg, had declined re-

Production increase at Tambar and Fogelberg update

27 April 2018 Faroe Petroleum plc ("Faroe", "Faroe Petroleum", the "Company") Production increase at Tambar and Fogelberg update Faroe Petroleum, the independent oil and gas company focusing principally on exploration, appraisal and production opportunities in Norway and the UK, is pleased to announce that both new infill wells drilled this year on the Tambar field in Norway, (Faroe 45%) have now been brought successfully on production.  We also provide an update on the Fogelberg well operation, in which a technical sidetrack will now be drilled ahead of the potential Drill Stem

There are no items matching the current filter
There are no more items matching the current filter
Back to top